Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXPRESSION
EGFR EXPRESSION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- 57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1709
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/354
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Cetuximab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 14993230
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Sensitivity | true |